INT144428

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 2004
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 41
Total Number 49
Disease Relevance 41.40
Pain Relevance 4.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Erbb2) plasma membrane (Erbb2) nucleus (Erbb2)
kinase activity (Erbb2) cytoplasm (Erbb2)
Anatomy Link Frequency
lung 14
exocrine pancreas 4
MDA-MB-468 2
MCF-7 2
brain 2
Erbb2 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 25 100.00 Very High Very High Very High
Inflammatory response 4 98.52 Very High Very High Very High
cytokine 15 97.40 Very High Very High Very High
imagery 74 97.20 Very High Very High Very High
chemokine 5 96.88 Very High Very High Very High
agonist 123 96.16 Very High Very High Very High
metalloproteinase 45 94.44 High High
Cannabinoid 513 93.48 High High
Central nervous system 257 92.24 High High
Chronic pancreatitis 4 92.12 High High
Disease Link Frequency Relevance Heat
Breast Cancer 899 100.00 Very High Very High Very High
Lung Cancer 147 100.00 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 137 99.98 Very High Very High Very High
Metastasis 534 99.92 Very High Very High Very High
Carcinoma 64 99.90 Very High Very High Very High
Targeted Disruption 28 99.86 Very High Very High Very High
Cancer 2063 99.76 Very High Very High Very High
Small Cell Lung Cancer 12 99.76 Very High Very High Very High
Non-small-cell Lung Cancer 88 99.68 Very High Very High Very High
Adenocarcinoma 38 99.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Many clinical studies have found an association between HER2 overexpression and Tamoxifen failure in metastatic breast cancer [42-45] and also a reduced response duration and survival duration in those treataed with adjuvant hormonal therapies.
Positive_regulation (overexpression) of Neg (failure) Gene_expression (overexpression) of HER2 associated with advanced or metastatic breast cancer
1) Confidence 0.69 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.40 Pain Relevance 0.13
They also showed that resistance to the cytotoxic effect of tumour necrosis factor alpha (a consequence of HER2 overexpression) was significantly reduced in the presence of the antibody.


Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 associated with necrosis and cancer
2) Confidence 0.69 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.73 Pain Relevance 0
Ridolfi et al (23) tested 750 consecutive invasive carcinomas for HER2 overexpression using both IHC and FISH techniques.
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 associated with carcinoma
3) Confidence 0.69 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.53 Pain Relevance 0
Although the trials are of relatively short followup duration, the treatment is associated with rare but significant side effects and the treatment is not without cost, Herceptin has undoubtedly made a real difference for those 25–30% of patients who overexpress the Her2/neu oncogene.
Positive_regulation (overexpress) of Gene_expression (overexpress) of Her2
4) Confidence 0.69 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.40 Pain Relevance 0
Several authors have reported a higher frequency of HER2 over expression in ductal carcinoma in situ (DCIS) compared with invasive cancer [19,20] Similarly, Liu et al [20] have observed HER2 overexpression as determined by gene amplification using polymerase-chain reaction (PCR)-based techniques in 48% of in situ carcinomas compared with 21% of stage II invasive breast tumours.
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 associated with cancer, breast cancer, carcinoma and noninfiltrating intraductal carcinoma
5) Confidence 0.69 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 1.43 Pain Relevance 0
Recently a meta-analysis of seven studies[47] concluded that metastatic breast cancer overexpressing HER2 was very likely to be resistant to Tamoxifen (odds ratio of disease progression, 2.46).
Positive_regulation (overexpressing) of Gene_expression (overexpressing) of HER2 associated with advanced or metastatic breast cancer and disease progression
6) Confidence 0.69 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.65 Pain Relevance 0.12
None of the hyperplastic/dysplastic breast lesions overexpressed HER2.
Positive_regulation (overexpressed) of Gene_expression (overexpressed) of HER2 associated with hyperplasia
7) Confidence 0.69 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 1.63 Pain Relevance 0
It targets the external moiety of the Her2 receptor and prevents activation of the protein (possibly by preventing dimerisation) thereby preventing proliferation of breast cancer cells overexpressing Her2.


Positive_regulation (overexpressing) of Gene_expression (overexpressing) of Her2 in external associated with breast cancer
8) Confidence 0.69 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.71 Pain Relevance 0.04
In addition, 43 patients with metastatic disease and HER-2 overexpression in the primary tumor were treated with Trastuzumab.
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER-2 associated with cancer and metastasis
9) Confidence 0.69 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779464 Disease Relevance 1.34 Pain Relevance 0.24
In particular, overexpression of HER2/neu (also known as ERBB2) has been found to correlate with increased tumor aggression, metastatic potential, and poor prognosis for disease-free survival in patients with breast, colorectal, ovarian, lung, prostate and salivary gland tumors.[6], [7] The ERBB signaling network and the role of HER2/neu in cancer biology has been the subject of several excellent reviews.[7]–[11]
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2/neu in lung associated with cancer, aggression and disease
10) Confidence 0.68 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2810330 Disease Relevance 0.62 Pain Relevance 0.09
The human NSCLC cell line A549 overexpresses both EGFR and HER-2 and may be an excellent model for testing the efficacy of lapatinib [7,8].
Positive_regulation (overexpresses) of Gene_expression (overexpresses) of HER-2 in A549 associated with non-small-cell lung cancer
11) Confidence 0.62 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2883966 Disease Relevance 0.98 Pain Relevance 0
In lung adenocarcinomas, both EGFR and HER-2 are overexpressed and this is associated with poor prognosis [5].
Positive_regulation (overexpressed) of Gene_expression (overexpressed) of HER-2 in lung associated with adenocarcinoma
12) Confidence 0.62 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2883966 Disease Relevance 1.12 Pain Relevance 0
Her-2 overexpression occurs in approximately 20–30% of breast cancers [15] and is also overexpressed in lung, ovarian and gastric adenocarcinomas [16].
Positive_regulation (overexpression) of Gene_expression (overexpression) of Her-2 in lung associated with adenocarcinoma and breast cancer
13) Confidence 0.60 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.88 Pain Relevance 0
Her-2 overexpression occurs in approximately 20–30% of breast cancers [15] and is also overexpressed in lung, ovarian and gastric adenocarcinomas [16].
Positive_regulation (overexpressed) of Gene_expression (overexpression) of Her-2 in lung associated with adenocarcinoma and breast cancer
14) Confidence 0.60 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.97 Pain Relevance 0
These data suggest that overexpression of ErbB2 in acinar cells leads to increased RAS activity without cell cycle progression and mediates inflammation via NF-kappaB.
Positive_regulation (overexpression) of Gene_expression (overexpression) of ErbB2 in acinar cells associated with inflammation
15) Confidence 0.55 Published 2007 Journal Int. J. Cancer Section Abstract Doc Link 17546589 Disease Relevance 0.59 Pain Relevance 0.28
Three independent transgenic mouse lines overexpressing ErbB2 were established by pronuclear injection.
Positive_regulation (overexpressing) of Gene_expression (overexpressing) of ErbB2 associated with targeted disruption
16) Confidence 0.55 Published 2007 Journal Int. J. Cancer Section Abstract Doc Link 17546589 Disease Relevance 0.43 Pain Relevance 0.13
Overexpression of ErbB2 in the exocrine pancreas induces an inflammatory response but not increased proliferation.
Positive_regulation (Overexpression) of Gene_expression (Overexpression) of ErbB2 in exocrine pancreas associated with inflammatory response and inflammation
17) Confidence 0.55 Published 2007 Journal Int. J. Cancer Section Title Doc Link 17546589 Disease Relevance 0.47 Pain Relevance 0.21
Overexpression of ErbB2 in the exocrine pancreas resulted in increased RAS activity and downstream activation of ERK1/2, but not in transgenic increased proliferation of acinar and ductal cells.
Positive_regulation (Overexpression) of Gene_expression (Overexpression) of ErbB2 in exocrine pancreas associated with targeted disruption
18) Confidence 0.55 Published 2007 Journal Int. J. Cancer Section Abstract Doc Link 17546589 Disease Relevance 0.54 Pain Relevance 0.20
This revealed that HER2 over expression was associated with an increased the risk of relapse/death by 75% (RR = 1.75).
Positive_regulation (increased) of Gene_expression (expression) of HER2 associated with death and recurrence
19) Confidence 0.50 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.87 Pain Relevance 0.03
The promoter of the HER-2 gene also contains an oestrogen response element which suppresses HER-2 expression on response to oestrogen and is overexpressed with tamoxifen [34,35].
Positive_regulation (overexpressed) of Gene_expression (overexpressed) of HER-2
20) Confidence 0.50 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.45 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox